Evidence map›Paper›PMID 38643076›Full record

Trial reportBMC pediatrics2024

The impact of combined administration of surfactant and intratracheal budesonide compared to surfactant alone on bronchopulmonary dysplasia (BPD) and mortality rate in preterm infants with respiratory distress syndrome: a single-blind randomized clinical trial.

Asghar Marzban, Samira Mokhtari, Pouria Tavakkolian, Reza Mansouri, Nahid Jafari, Azam Maleki

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC pediatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 4 pooled it
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Asghar MarzbanDept. of neonatology, School of Medicine, Musavi hospital, Zanjan university of medical sciences, Zanjan, Iran.ORCID http://orcid.org/0000-0003-1226-3345
Samira MokhtariDept. of neonatology, School of Medicine, Musavi hospital, Zanjan university of medical sciences, Zanjan, Iran.ORCID http://orcid.org/0000-0001-9140-4868
Pouria TavakkolianStudent Research Center, Zanjan University of Medical Sciences, Zanjan, Iran.ORCID http://orcid.org/0000-0002-8893-2456
Reza MansouriDepartment of Hematology & Medical Oncology, Vali-e-Asr Hospital, Zanjan University of Medical Sciences, Zanjan, Iran.ORCID http://orcid.org/0000-0003-0836-299X
Nahid JafariDept. of neonatology, School of Medicine, Musavi hospital, Zanjan university of medical sciences, Zanjan, Iran.ORCID http://orcid.org/0000-0001-5255-824X
Azam MalekiSocial Determinants of Health Research Center, Health and Metabolic Diseases Research Institute, Zanjan University of Medical Sciences, Azadi Square, Jomhori Eslami St, Zanjan, 4515613191, Iran. malekia@zums.ac.ir.ORCID http://orcid.org/0000-0001-7888-1985
Zanjan University of Medical Sciences · IR

Funding

Zanjan University of Medical Sciences A-12-306-7
6 · The paper itself

Abstract

backgroundRespiratory distress syndrome (RDS) is one of the most important and common disorders among premature infants.

objectiveThis study aimed to compare the effect of the combination of surfactant and budesonide with surfactant alone on Bronchopulmonary dysplasia (BPD) and mortality rate among premature infants with RDS.

methodAn outcome assessor-blind randomized clinical trial was conducted on 134 premature infants with RDS who were born in Ayatollah Mousavi Hospital, Zanjan, Iran in 2021. The covariate adaptive randomization method was utilized to allocate participants into two groups (surfactant alone and a combination of surfactant and budesonide). The primary outcomes were BPD and Mortality rate from admission to hospital discharge. The data in this study were analyzed using SPSS software version 18.

resultsOverall the comparison of mortality rate and BPD between the two groups did not show a significant difference(p > 0.05). The subgroup results showed that administering surfactant with budesonide to infants under 30 weeks of age significantly reduced the number of deaths compared to using surfactant alone (5 vs. 17). Similar positive effects were observed for the occurrence of Pulmonary Hemorrhage, the need for a second dose of surfactant, oxygen index, mean blood pressure and mean arterial pressure (MAP) in infants under 34 weeks of age compared to more than 34 weeks (p < 0.05).

conclusionThese findings suggest that the combination therapy of surfactant and budesonide may be beneficial, particularly in preterm infants with less than 34 weeks gestational age and 1500 birth weight. However, further studies with larger sample sizes and longer follow-up periods are needed to confirm these results and assess long-term outcomes.

trial registrationThe study was registered at the Iranian Registry of Clinical Trials website under the code IRCT20201222049802N1. https://en.irct.ir/user/trial/48117/view . REGISTRATION DATE: 28/02/2021. PUBLIC REPOSITORY: DATA SET: This research data set link is displayed on the Zanjan-Iran Medical Sciences website: https://repository.zums.ac.ir/cgi/users/login? target=https%3 A%2 F/repository.zums.ac.ir/id/eprint .

Indexed as

Bronchopulmonary DysplasiaPulmonary SurfactantsRespiratory Distress Syndrome, NewbornBudesonideHumansInfantInfant, NewbornInfant, PrematureIranLipoproteinsRespiration, ArtificialSingle-Blind MethodSurface-Active AgentsBudesonideLipoproteinsPulmonary SurfactantsSurface-Active AgentsBudesonidePremature neonateRespiratory distress syndromeSurfactant

Identifiers

PMID38643076
PMCPMC11031862
OpenAlexW4394975958

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.